Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)
Phase 2
Recruiting
- Conditions
- Solid Tumor, Adult
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 25
- Registration Number
- NCT06032845
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Home Telemonitoring System for Wearable Fetal-ECG and EHG Acquisition During Pregnancy
Completed
- Conditions
- Pregnancy RelatedHome RangeUterine Contractions; ProlongedFetal Heart Rate or Rhythm Abnormality Affecting Fetus
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 4
- Registration Number
- NCT06031142
- Locations
- 🇨🇳
FetaCare, Shanghai, Pudong New District， Shanghai, China
Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin
Phase 2
- Conditions
- Gastric / Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06030934
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
Phase 3
Recruiting
- Conditions
- Sublobar ResectionFrozen SectionLung Adenocarcinoma
- Interventions
- Procedure: Sublobar Resection
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 390
- Registration Number
- NCT06031181
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
Phase 3
Recruiting
- Conditions
- Lymph Node MetastasisLung Adenocarcinoma
- Interventions
- Procedure: Selective Lymph Node Dissection
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 634
- Registration Number
- NCT06031246
- Locations
- 🇨🇳
Chaoqiang Deng, Shanghai, Please Select, China
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Completed
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: Targeted agent
- First Posted Date
- 2023-09-07
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 198
- Registration Number
- NCT06027775
Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Exposure, Repair or Reconstruction
Not Applicable
Completed
- Conditions
- Pancreatic Tumor, BenignSolid Pseudopapillary Tumor of the PancreasPancreatic Neuroendocrine Tumor
- Interventions
- Procedure: MPD Repair or Reconstruction
- First Posted Date
- 2023-09-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 230
- Registration Number
- NCT06024343
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases
Completed
- Conditions
- The Patients With CRLM Who Benefit More From Bevacizumab
- Interventions
- Diagnostic Test: Deep radiomics-based fusion model
- First Posted Date
- 2023-09-05
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 307
- Registration Number
- NCT06023173
- Locations
- 🇨🇳
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Phase 2
Recruiting
- Conditions
- Brain MetastasesNon-small Cell Lung Cancer
- Interventions
- Drug: EGFR-TK InhibitorRadiation: Stereotactic radiotherapy
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 202
- Registration Number
- NCT06020066
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer
Phase 3
Recruiting
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2023-08-31
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06018883
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath